The efficacy and safety of mometasone furoate delivered via a dry powder inhaler for the treatment of asthma.
Inhaled corticosteroids are the gold standard of daily therapy for effective control of all stages of persistent asthma. For this review of the new inhaled corticosteroid mometasone furoate, a MEDLINE/PubMed search using the terms "mometasone furoate AND asthma" found 57 articles, 17 of which presented data from efficacy and safety studies reviewed herein. In clinical trials, once-daily evening dosing of mometasone furoate delivered via dry powder inhaler (200 or 400 mu g/day) was effective in patients with mild to moderate asthma previously treated with short-acting beta2-agonists alone and in those previously maintained on inhaled corticosteroid therapy. In patients with severe asthma, mometasone furoate 400 mu g twice daily eliminated or reduced the need for oral prednisone while improving lung function, asthma symptoms, and quality of life. Clinical studies have shown that mometasone furoate is generally well tolerated and has minimal systemic activity at recommended doses. In conclusion, mometasone furoate provides primary care and specialty physicians with a safe, effective, and convenient option to meet the challenges of asthma management.
Meltzer
Eli O
EO
Allergy and Asthma Medical Group and Research Center, University of California-San Diego, 9610 Granite Ridge Drive, San Diego, CA 92123, USA. eomeltzer@aol.com
Wenzel
Sally
S
D018927:Anti-Asthmatic Agents / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D006801:Humans; D000068656:Mometasone Furoate; D009330:Nebulizers and Vaporizers; D011208:Powders; D011244:Pregnadienediols / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
D018927:Anti-Asthmatic Agents; D011208:Powders; D011244:Pregnadienediols; D000068656:Mometasone Furoate